BioSpace News Archive

NeoImmuneTech, Inc. today announced that new data from a Phase 1/2 study evaluating the company’s lead asset NT-I7 (efineptakin alfa) will be presented during oral abstract sessions at the Society for Neuro-Oncology (SNO) annual meeting, to be held in Boston, Massachusetts on November 18-21, 2021.

Spectrum Pharmaceuticals today announced a late-breaking presentation of early poziotinib efficacy and safety data in first-line patients with non-small cell lung cancer (NSCLC) with HER2 exon 20 mutations from cohort 4 of the ZENITH20 clinical trial at the upcoming European Society for Medical Oncology Congress (ESMO) 2021 that will take place virtually September 16-20, 2021.

LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, announced the 2021 award recipients for two new Health Equity and Inclusiveness award programs.

NeoDynamics has demonstrated its novel biopsy system NeoNavia at two scientific congresses in Austria and Switzerland in September.

SIGA Technologies, Inc. announced the exercise of a procurement option under its 75A50118C00019 contract with Biomedical Advanced Research and Development Authority, part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services for the delivery of oral TPOXX® treatment courses valued at approximately $112.5 million to the U.S. government.

Saliva is an optimal diagnostic body-fluid comprised of several synthesized and systemic proteins, act as a salivary biomarkers.

Driven by the shifting paradigms of patients from ‘treatment’ to ‘wellness’, the healthcare industry has been advancing with significant breakthroughs in recent times.

Transparency Market Research has published a new report titled, ‘Human vaccine Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.

Development in the healthcare sector has also been of the key focus in North American region.

Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, announced that the U.S. Food and Drug Administration has approved the initiation of a Phase 1 clinical trial of HMBD-002, Hummingbird’s anti-VISTA neutralizing antibody.